Ligand Pharma (LGND) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $298.50 --0%
Revenue Growth %: -32.2%
Financial Fact:
Income tax expense (benefit): -160K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -32.2%
Financial Fact:
Income tax expense (benefit): -160K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $21.6 million versus the consensus estimate of $23.13 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
- KB Home (KBH) Tops Q3 EPS by 16c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
